Veritas In Silico Inc.
Basic information
- Head office
- 1-11-1 Nishigotanda, Shinagawa-ku, Tokyo
- Chief executive
- Shingo Nakamura
- Capital
- 10,000,000
- Employees (non-consolidated)
- 18 people
- Employees (consolidated)
- 23 people
- Start date
- 2016-11-17
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Teijin Pharma Limited | ||||||||
| Asahi Kasei Pharma Corporation | ||||||||
| Takeda Pharmaceutical Company, Limited | ||||||||
| かわさき新産業創造センター(KBIC) | ||||||||
| Oncodesign Services | ||||||||
| 三菱ガス化学 | ||||||||
| Emina Corporation | ||||||||
| 東京慈恵会医科大学 |
Network
History
Veritas In Silico was founded. Based on in‑silico RNA structural analysis technology, the company aimed to develop low‑molecular‑weight drugs and nucleic‑acid drugs targeting mRNA, and was established in Shibuya-ku, Tokyo.![]()
Veritas In Silico was founded. Based on in‑silico RNA structural analysis technology, the company aimed to develop low‑molecular‑weight drugs and nucleic‑acid drugs targeting mRNA, and was established in Shibuya-ku, Tokyo.![]()
Received Series A funding from Mitsubishi Gas Chemical Corporation (MGC) and three venture capital firms, marking the official launch.![]()
Conducted Series A fundraising. Received Series A funding from Mitsubishi Gas Chemical Corporation (MGC) and three venture capital firms, marking the official launch.![]()
Established a research base at Niigata College of Pharmacy. Professor Masayuki Irimoto, who belongs to the university, set up the research base.![]()
Established a research base at Niigata College of Pharmacy. Set up a research base at Niigata College of Pharmacy (Niigata City, Niigata Prefecture), where Professor Masayuki Irimoto, a leading figure in the sgASO field, belongs.![]()
Commenced joint research on mRNA‑targeted low‑molecular‑weight drug development with domestic pharmaceutical companies.![]()
Start of joint research with a pharmaceutical company on mRNA-targeted small molecule drug discovery. The first joint research with a domestic pharmaceutical company in the mRNA-targeted small molecule drug discovery business has begun.![]()
Established a research base for the mRNA‑targeted low‑molecular‑weight drug development business at the Kawasaki New Industry Creation Center (KBIC) in Kawasaki City, Kanagawa Prefecture.![]()
Establishment of a research base in Shin-Kawasaki. A research base for the mRNA-targeted small molecule drug discovery business has been established at the Kawasaki New Industry Creation Center – KBIC (Kawasaki City, Kanagawa Prefecture).![]()
Focused on the low‑molecular‑weight drug development business by conducting Series B fundraising. In addition to existing shareholders, received investment from three venture capital firms, and decided to actively pursue the low‑molecular‑weight drug development business.![]()
Series B fundraising. In order to focus on the small molecule drug discovery business, a Series B round of fundraising was conducted to confirm the intentions of shareholders. In addition to existing shareholders, we received investment from three venture capital firms that support the small molecule drug discovery business, and decided to seriously pursue the small molecule drug discovery business.![]()
Obtained a patent in Japan for a business model of low‑molecular‑weight drug development targeting RNA.![]()
Patent acquisition related to the business model. A patent related to the business model of small molecule drug discovery targeting RNA has been obtained (Japan).![]()
Decided to expand the drug discovery platform business for low‑molecular‑weight drugs targeting mRNA through the development and introduction of new technologies.![]()
Series C fundraising. Decided on a strategy to expand the platform business for discovering small molecule drugs targeting mRNA through the development and introduction of new technologies.![]()
Signed a memorandum of understanding (MOU) for business cooperation with Oncodesign Services, a French contract research organization (CRO), to broadly meet the needs of pharmaceutical companies aiming to develop low‑molecular‑weight drugs targeting mRNA.![]()
Business cooperation with a CRO. To broadly meet the needs of pharmaceutical companies aiming to develop small molecule drugs targeting mRNA, a basic agreement (MOU) on business cooperation was signed with Oncodesign Services, a French contract research organization (CRO).![]()
Conducting joint drug discovery research aimed at developing mRNA‑targeted low‑molecular‑weight drugs with Toray Industries, Shionogi & Co., Ltd., Rakuoia Drug Discovery, and Takeda Pharmaceutical Company, Ltd.![]()
News
There is no news.
Public records
National Tax Agency basic information4011001113744
- Trade name
- 株式会社Veritas In Silico
- Trade name (kana)
- ウェリタスインシリコ
- Name in English
- Corporation type
- 301
- Address
- 〒141-0031 東京都品川区西五反田1丁目11番1号
- Postal code
- 1410031
- Prefecture code
- 13
- City code
- 109
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2016-11-24
- Update date
- 2023-12-20
- Change date
- 2017-10-31
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 12
- Correction type
- 1
- Trade name image ID
- Address image ID
- Sequence number
- 1791934
METI gBizINFO4011001113744
- Corporate number
- 4011001113744
- Trade name
- 株式会社Veritas In Silico
- Trade name (kana)
- ウェリタスインシリコ
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 東京都品川区西五反田1丁目11番1号
- Postal code
- 1410031
- Prefecture
- 東京都
- Prefecture code
- 13
- City or district
- 品川区
- City code
- 109
- Street address
- 西五反田1丁目11番1号
- Organisation type
- 301
- Processing type
- 12
- Correction type
- 1
- Status
- Representative
- 代表取締役社長 中村 慎吾
- Capital
- 10000000
- Employees
- 19
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2023-12-20
- Key information
- 4011001113744